We tested the hypothesis that simulataneous targeting of the epidermal growth factor receptor ( EGFR ) and insulin-like growth factor receptor-1 ( IGF-1R ) pathways would significantly improve progression-free survival ( PFS ) by abrogating reciprocal signaling that promote drug resistance